FDA sends Genentech 483 after finding failings at Avastin plant
The US FDA has sent Genentech a GMP 483 after inspectors found failings in the capping process for Avastin.
Archives for November 8, 2011
Tranzyme and B-MS extend their drug discovery collaboration
Tranzyme Pharma has extended its drug discovery collaboration with Bristol-Myers Squibb.
Establishing R&D bonds is wave of the future, says Lilly boss
Drug researchers must integrate development programs more to drive the industry into the 21st century, says Eli Lilly CEO John Lechleiter.
BASF to enter synthetic menthol market in 2012
BASF will start producing synthetic menthol next year using a new method that, it claims, offers significant quality and supply advantages for drug and food manufacturers.
Private equity buys WellSpring and its CMO business
A private equity consortium has bought WellSpring Pharmaceutical and its Canadian contract manufacturing plant.
Contrasting early phase performance for CRL and Covance in Q3
Charles River Laboratories (CRL) continued to experience low demand for preclinical services in Q3, while Covance's early-phase business saw revenue growth.
Cyprotex invests to meet demand for cell-based preclinical tox
Cyprotex says increasing demand for cell-based preclinical toxicology services in North America prompted facility expansion plan.
Chinese FDA should hire CMC staff to boost QbD; Pfizer exec
The Chinese FDA should hire more CMC reviewers to encourage QbD applications, a Pfizer executive said.